Novartis To Spin Off $9.6B Sandoz Generic Drugs Biz
Swiss-American pharmaceuticals giant Novartis AG said Thursday that it plans to separate its Sandoz generic drugs division from its core business of developing innovative medicines to form a standalone publicly traded...To view the full article, register now.
Already a subscriber? Click here to view full article